Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing in its clinical study for SKG0106 intraocular injection solution. This in-house developed ophthalmology gene therapy was approved for clinical trials in China in December 2022. The open, dosage escalation study is designed to evaluate the safety, initial efficacy, immunogenicity, and pharmacokinetics of the drug candidate in treating neovascular (wet) age-related macular degeneration (wAMD).
SKG0106: A Novel rAAV Gene Therapy for wAMD
SKG0106 is an innovative recombinant adeno-associated virus (rAAV) gene therapy drug. It is carried by a novel AAV capsid that encodes a unique gene sequence responsible for anti-VEGF protein. This protein plays a crucial role in resisting neovascularization. After a single intravitreal injection, SKG0106 efficiently transduces retinal cells in the eye, continuously expressing functional proteins that combat the progression of neovascularization. By blocking vascular leakage and retinal edema, SKG0106 has the potential to significantly slow down the progression of nAMD.
The Potential Impact of SKG0106 on Ophthalmology
The initiation of patient dosing in the clinical trial for SKG0106 signifies a step forward in the development of gene therapy for ophthalmic conditions. This approach has the potential to transform the treatment landscape for patients suffering from wAMD, offering a targeted and sustained treatment option.-Fineline Info & Tech
